Navigation Links
Sonic Innovations Announces Results for Third Quarter 2008
Date:10/28/2008

Record Third Quarter Sales

SALT LAKE CITY, Oct. 28 /PRNewswire-FirstCall/ -- Sonic Innovations, Inc. (Nasdaq: SNCI), a leading producer of advanced digital hearing aids, today announced results for the third quarter ended September 30, 2008.

Third quarter highlights:

-- Achieved record third quarter sales from continuing operations of

$31.3 million and realized 4.3 percent sales growth compared to third

quarter 2007.

-- Launched three new products to further strengthen our product lineup.

-- Substantially completed the consolidation of European operations.

"In the third quarter of 2008, we launched three new products including two at the lower end of the price spectrum, which should drive our sales in a soft economy," said Sam Westover, Chairman and CEO. "Our consolidation activities are virtually completed in Europe and we are seeing improved performance from these efforts."

Record third quarter 2008 net sales from continuing operations of $31.3 million were 4.3 percent higher than third quarter 2007 sales of $30.0 million. North American sales of $11.9 million in the third quarter 2008 decreased 5.4 percent from 2007. European sales of $11.7 million in the third quarter 2008 increased 8.9 percent from 2007. Rest-of-world sales of $7.7 million in the third quarter 2008 were up 15.2 percent from 2007.

Net sales from continuing operations of $97.6 million for the nine months ended September 30, 2008 increased 12.0 percent over the same period in 2007. Net sales increased by 2.3 percent in North America, 13.8 percent in Europe and 27.7 percent for rest-of-world for the first nine months of 2008 compared to 2007.

Gross profit from continuing operations of $20.1 million in the third quarter 2008 increased 6.5 percent from 2007. Gross margin from continuing operations for the third quarter was 64.3 percent in 2008 compared to last year's third quarter level of 62.9 percent as a result of cost reductions in manufacturing, distribution activities, lower warranty costs, and changes in foreign currency exchange rates.

The Company's gross profit from continuing operations increased to 63.5 percent for the nine months ended September 30, 2008 from 62.8 percent for the same nine months of 2007.

Selling, general and administrative expense as a percentage of net sales from continuing operations increased from 54.4 percent in the third quarter 2007 to 57.5 percent in the third quarter 2008 as a result of retail acquisitions and changes in foreign currency exchange rates. Research and development expense in the third quarter 2008 of $2.0 million was down $0.1 million from $2.1 million in the prior year.

The Company expects that consolidation activities will result in total restructuring charges of approximately $2.5 million in non-cash charges and $2.4 million in cash charges in 2008. Restructuring charges from continuing operations are expected to be $0.3 million and $2.3 million in non-cash and cash charges, respectively. For the third quarter of 2008, the Company recorded total restructuring charges of $0.4 million, or $0.01 per share, and $4.1 million, or $0.15 per share, on a year-to-date basis. In the third quarter of 2008, the Company recorded restructuring charges from continuing operations of $0.2 million, or $0.01 per share, and $1.6 million, or $0.06 per share, on a year-to-date basis.

Income from continuing operations for the third quarter of 2008 was $0.6 million, or $0.02 per share, compared to income $0.7 million, or $0.03 per share, for the third quarter 2007.

The year-to-date loss from continuing operations for the nine months ended September 30, 2008 was $0.5 million, or $0.02 per share, as compared with income from continuing operations of $1.1 million or $0.04 per share, for the nine months ended September 30, 2007.

During the third quarter 2008, the Company recognized a tax benefit on the reversal of a deferred tax asset valuation allowance of $1.3 million related to its Australian operation.

In the third quarter 2008, the Company closed one of its European operations and sold another operation in Europe as part of the consolidation efforts. These units have been classified as discontinued operations for the three and nine months ended September 30, 2008, and 2007, respectively.

As of September 30, 2008, the Company had cash and cash equivalents of $13.6 million and an available line of credit of $6.0 million.

Sonic Innovations designs, develops, manufactures and markets advanced digital hearing aids designed to provide the highest levels of satisfaction for hearing impaired consumers.

This press release contains "forward-looking statements" as defined under securities laws including, (i) our expectation that our consolidation efforts will improve our earnings growth going forward. Actual results may differ materially and adversely from those described herein depending on a number of factors but not limited to, the following risks: we face aggressive competition in our business; acquisitions could be difficult to integrate and disrupt our current business and therefore may harm our operating results; we may poorly operate newly acquired businesses; our consolidation initiative may not produce the cost savings or may take longer or be more difficult than we anticipate; our consolidation initiative may divert a significant amount of management's resources and attention away from other matters or may adversely affect other segments of our business; our new products may not increase sales; we may lose a large customer or suffer a reduction in orders from a large customer; we must have innovative, technologically superior products to compete effectively; our products, due to their complexity, may contain errors or defects that are only discovered after sales by our customers, thus harming our reputation and business; we may have issues with intellectual property; and we have important international operations, which expose us to a variety of risks including government reimbursement, that could impact sales and operating results. For additional information regarding the risks inherent in our business, please see "Factors That May Affect Future Performance" included in our Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission.

This press release contains two non-GAAP ("Generally Accepted Accounting Principles") financial measures ("EBITDA" and "INCOME (LOSS) FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED INCOME FROM CONTINUING OPERATIONS"). We believe the inclusion of such non-GAAP financial measure improves the transparency of our disclosure. We have provided reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures.

We undertake no obligation to revise our forward-looking statements to reflect events or circumstances after the date hereof as a result of new information, future events or otherwise.

The Company will host a teleconference call in connection with this release on Tuesday, October 28, 2008 at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time).

To participate in the conference call, please call toll free (866) 831-6243, or (617) 213-8855 outside the U.S., and use participant passcode: 45891062. A live webcast will also be available through our website at http://www.sonici.com. You may also visit our website for an archive of prior press releases and earnings announcements.

If you wish to hear a digital playback of the call, please dial (888) 286-8010 within the U.S., or (617) 801-6888 outside the U.S., and enter passcode 10789169 (available through October 31, 2008, midnight), or access the playback through our website.

SONIC INNOVATIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Net sales $31,311 $30,021 $97,598 $87,154

Cost of sales 11,193 11,138 35,581 32,390

Gross profit 20,118 18,883 62,017 54,764

Selling, general and

administrative expense 18,013 16,340 55,013 47,215

Research and development

expense 2,005 2,108 6,387 6,572

Restructuring charges 232 - 1,561 -

Operating income (loss) (132) 435 (944) 977

Other income (expense), net (137) 385 110 715

Income (loss) before

income taxes (269) 820 (834) 1,692

Provision (credit) for

income taxes (910) 95 (321) 641

Income (loss) from

continuing operations 641 725 (513) 1,051

Income (loss) from

discontinued operations,

net of income taxes (344) (244) (3,724) (433)

Net income (loss) $297 $481 $(4,237) $618

Basic income (loss) per

common share:

Continuing operations $0.02 $0.03 $(0.02) $0.04

Discontinued operations (0.01) (0.01) (0.14) (0.02)

Net income (loss) $0.01 $0.02 $(0.16) $0.02

Diluted income (loss)

per common share:

Continuing operations $0.02 $0.03 $(0.02) $0.04

Discontinued operations (0.01) (0.01) (0.14) (0.02)

Net income (loss) $0.01 $0.02 $(0.16) $0.02

Weighted average number of

common shares outstanding:

Basic 27,489 26,721 27,226 26,436

Diluted 27,541 27,726 27,226 27,492

SONIC INNOVATIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(in thousands)

(unaudited)

September 30, December 31,

2008 2007

Assets:

Cash and cash equivalents $13,595 $20,684

Accounts receivable 20,338 21,996

Inventories 10,881 13,451

Property and equipment 7,197 8,267

Goodwill and intangibles 55,835 52,837

Other assets 8,320 6,466

Total assets $116,166 $123,701

Liabilities:

Accounts payable and accrued liabilities $23,756 $26,546

Loans payable 7,953 10,820

Deferred revenue 10,294 10,102

Total liabilities 42,003 47,468

Shareholders' equity:

Common stock 29 28

Additional paid-in capital 143,479 139,853

Accumulated deficit (75,505) (71,268)

Other 6,160 7,620

Total shareholders' equity 74,163 76,233

Total liabilities and shareholders' equity $116,166 $123,701

SONIC INNOVATIONS, INC.

CONSOLIDATED STATEMENT OF NET SALES INFORMATION

(in thousands)

(unaudited)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Hearing aids:

North America $11,899 $12,578 $36,131 $35,314

Europe 11,726 10,769 38,557 33,896

Rest-of-world 7,686 6,674 22,910 17,944

Total $31,311 $30,021 $97,598 $87,154 EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION ("EBITDA")

(in thousands)

(unaudited)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Income (loss) from

continuing operations $641 $725 $(513) $1,051

Add back (deduct):

Interest (income)

expense, net 72 (83) 107 (329)

Taxes (910) 95 (321) 641

Depreciation and

amortization 1,272 1,113 3,758 3,119

EBITDA $1,075 $1,850 $3,031 $4,482 INCOME (LOSS) FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED INCOME FROM

CONTINUING OPERATIONS

(in thousands)

(unaudited)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Income (loss) from

continuing operations $641 $725 $(513) $1,051

Add back (deduct):

Restructuring

charges 232 - 1,561 -

Restructured

operations (1) (79) 521 951 692

Adjusted income from

continuing operations $794 $1,246 $1,999 $1,743

(1) The restructured operations include two European locations subject to

the Company's consolidation efforts.


'/>"/>
SOURCE Sonic Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sonic Foundry to Host Wisconsin Lt. Governor Lawton in Raising Awareness for National Depression Screening Day
2. Sonic Innovations Announces Results for Fourth Quarter and Full Year 2007
3. Sonic Innovations Not Included in Adverse Jury Verdict
4. Sonic Innovations Celebrates 10-Year Anniversary
5. Sonic Innovations Launches Two New Hearing Aid Products in Conjunction With Companys 10-Year Anniversary
6. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
7. OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY
8. Sam Westover to Serve as Chairman of the Board and Chief Executive Officer for Sonic Innovations
9. AUDIO from Medialink, Oral Health America & Philips Sonicare: National Smile Month - Giving Americans Something to Smile About Survey Reveals State of Americans Oral Health
10. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
11. Sonic Innovations Announces Loan Amendment With German Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: